Quarterly report pursuant to Section 13 or 15(d)

Accounting Policies and Merger Pro Forma Adjustments - Schedule of Pro Formo Weighted Average Common Shares Outstanding (Details)

v3.21.1
Accounting Policies and Merger Pro Forma Adjustments - Schedule of Pro Formo Weighted Average Common Shares Outstanding (Details) - shares
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Estimated adjusted total shares of common stock for the combined entity 8,544,298 1,113,737
Pro Forma [Member]    
Common shares issued and outstanding 37,282,520  
Estimated adjusted total shares of common stock for the combined entity [1] 37,500,088  
Akers pre-merger [Member] | Pro Forma [Member]    
Common shares issued and outstanding [1],[2] 8,544,298  
Akers post-merger [Member] | Pro Forma [Member]    
Estimated adjusted total shares of common stock for the combined entity [1] 8,946,781  
Series D Convertible Preferred stock converted to common stock [1]  
Restricted Stock Units converted to common stock; vesting accelerated to the effective date [1] 402,483  
Pre-funded warrants convertible to common stock [1]  
All Shares Issued/Issuable Upon Merger [Member]    
Estimated adjusted total shares of common stock for the combined entity 42,493,817  
All Shares Issued/Issuable Upon Merger [Member] | Akers pre-merger [Member]    
Common shares issued and outstanding [2] 8,326,730  
All Shares Issued/Issuable Upon Merger [Member] | Akers post-merger [Member]    
Estimated adjusted total shares of common stock for the combined entity 9,752,195  
Series D Convertible Preferred stock converted to common stock 36,496  
Restricted Stock Units converted to common stock; vesting accelerated to the effective date 402,483  
Pre-funded warrants convertible to common stock 986,486  
MyMD Pharmaceuticals, Inc., [Member] | MYMD pre-merger [Member] | Pro Forma [Member]    
Common shares issued and outstanding [1]  
Stock options outstanding [1]  
Total pre-Merger MyMD Florida share basis [1]  
Post conversion basis at the Exchange Ratio of 0.7718 [1]  
Effect of 1-for-2 reverse stock split  
Post reverse split basis at the Exchange Ratio of 0.7718 [1]  
Recapitalization/Conversion of pre-Merger MyMD Florida common shares into Company common shares based on the Exchange Ratio: [1] 28,533,307  
Recapitalization/Conversion of pre-Merger MyMD Florida stock options into Company common shares based on the Exchange Ratio(1) [1],[3]  
Estimated adjusted total shares of common stock for the combined entity [1] 28,533,307  
MyMD Pharmaceuticals, Inc., [Member] | All Shares Issued/Issuable Upon Merger [Member] | MYMD pre-merger [Member]    
Common shares issued and outstanding 73,911,413  
Stock options outstanding 10,853,360  
Total pre-Merger MyMD Florida share basis 84,844,773  
Post conversion basis at the Exchange Ratio of 0.7718 65,479,931  
Effect of 1-for-2 reverse stock split (32,738,309)  
Post reverse split basis at the Exchange Ratio of 0.7718 32,741,622  
Recapitalization/Conversion of pre-Merger MyMD Florida common shares into Company common shares based on the Exchange Ratio: 28,553,307  
Recapitalization/Conversion of pre-Merger MyMD Florida stock options into Company common shares based on the Exchange Ratio(1) [3] 4,188,315  
Estimated adjusted total shares of common stock for the combined entity 32,741,622  
[1] All outstanding stock options, Series D convertible preferred stock and pre-funded warrants exercisable for the combined company's common stock are anti-dilutive and therefore excluded from the weighted-average shares calculation for the three months ended March 31, 2021 as referenced in the pro forma condensed combined Statement of Comprehensive Loss.
[2] The Company's pre-Merger common shares issued and outstanding of 8,326,730 was the actual number of common shares issued and outstanding as of March 31, 2021.
[3] Pursuant to the terms of the Merger Agreement, shares have been allocated to pre-Merger MyMD Florida's outstanding stock options, however, there is no requirement for these options to be exercised as of the effective date of the Merger and are therefore being treated as unissued shares for the purposes of calculating the weighted-shares outstanding